ArticleJournal of clinical medicine2025

Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks.

Nosheen Reza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.